FDA Emergency Use Authorization awarded to the Beckman Coulter Access IL-6 test

The Access Interleukin-6 (IL-6) assay is designed to assist physicians in the identification of severe inflammatory response in COVID-19 patients

BREA, CALIF., OCT. 1, 2020 —Beckman Coulter today announced that it has received Emergency Use Authorization (EUA) for its Access Interleukin-6 (IL-6) assay from the U.S. Food & Drug Administration (FDA). Access IL-6 is a fully automated immunoassay designed to detect IL-6 levels in serum and plasma which can be used to aid physicians identifying a severe inflammatory response and determining the risk of intubation with mechanical ventilation in COVID-19 patients.

IL-6 is a multifunctional cytokine that may promote inflammation in certain clinical conditions. Preliminary studies¹ have shown that the IL-6 level is elevated in patients with severe COVID-19 and IL-6 may contribute to the severe inflammatory response, also sometimes referred to as cytokine storm.

“Our goal is to keep patients off the ventilator as that’s the best way to help COVID-19 patients. IL-6 can help us treat the patient before they need a ventilator. The side effect of this is that we are able to reduce the number of patients on ventilators to preserve capacity if needed in a hospital,” said Joshua Hayden, Ph.D., DABCC, Chief of Chemistry, Norton Healthcare. “Any time you can have more objective measures, such as testing with IL-6 to predict which patients are going to get worse, it is helpful. I highly encourage places that have to make rationing decisions to use markers such as IL-6 to assist them.”

Mao Eniang, professor & head of emergency medicine, Ruijin Hospital; Medical School of Shanghai Jiao Tong University said, “We have learned that monitoring IL-6 levels in COVID-19 patients has become an extremely important factor in the management of these individuals, in conjunction with clinical findings and the results of other laboratory testing. Clinical cases and data suggest that cytokine storms are accompanied by high expression of IL-6 protein. We have also seen that cytokine storms, characterized by elevated IL-6 levels, may be a key factor in the deterioration of patients with severe COVID-19^2,3. While cytokine storms can be the result of many types of bacterial or viral infections, burns, surgical wounds, and other diseases, they develop differently depending upon the clinical scenario.”

In COVID-19 patients, pulmonary inflammation makes oxygenation more difficult and can eventually lead to acute lung injury, pneumonia or acute respiratory distress syndrome (ARDS), among other conditions. Accumulating evidence suggests that a subgroup of patients^4,5 with severe COVID-19 experience increased levels of IL-6, and studies recommend^6,7,8 identification and treatment of hyperinflammation using existing, approved therapies with proven safety profiles to address the immediate need to reduce the rising mortality⁹. Early studies have shown that, in conjunction with other clinical findings, Access IL-6 testing results could guide patient management by identifying patients at risk for intubation with mechanical ventilation.

“An assay that helps identify patients at risk for respiratory failure and intubation in the care pathway has the potential to significantly improve COVID-19 patient care and outcomes,” said Shamiram R. Feinglass, M.D., MPH, chief medical officer for Beckman Coulter. “Access IL-6 is used to assist in identifying severe inflammatory response in patients with confirmed COVID 19 illness to aid in determining the risk of intubation with mechanical ventilation. In conjunction with clinical findings and the results of other laboratory testing, this assay provides clinicians with vital information enabling them to make decisions on how to manage these critically ill patients.”

To learn more about the Access IL-6 assay, or for the latest information on Beckman Coulter’s response to COVID-19, visit www.beckmancoulter.com/coronavirus.

About Beckman Coulter
Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology and the passion and creativity of our teams to enhance the diagnostic laboratory’s role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. Beckman Coulter offers a unique combination of people, processes and solutions designed to elevate the performance of clinical laboratories and healthcare networks. We do this by accelerating care with a menu that matters, bringing the benefit of automation to all, delivering greater insights through clinical informatics and unlocking hidden value through performance partnership. An operating company of Danaher Corporation (NYSE: DHR) since 2011, Beckman Coulter is headquartered in Brea, Calif., and has more than 11,000 global associates working diligently to make the world a healthier place.

###